AI and Federal Policy Rules Spark Both Hope and Caution at Biotech’s Biggest Conference

AI and Federal Policy Rules Spark Both Hope and Caution at Biotech’s Biggest Conference

The annual BIO conference, the largest gathering of the biotech industry, saw its mood shaped by two dominant forces this year: the rapid rise of artificial intelligence and shifting federal policy.

· 1 min read ·

Artificial intelligence was a central topic of discussion, with companies racing to use the technology to speed up drug discovery and cut costs. However, the excitement over AI’s potential was tempered by questions about how it will be regulated [183396]. At the same time, new federal rules and ongoing funding debates are forcing biotech firms to rethink their strategies, creating an atmosphere that felt both hopeful and cautious [183396]. Reporters from STAT, who attended the event in person, described the energy inside the convention halls as a mix of optimism and uncertainty [183396].

Sources

Related